ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

By F. Carlomagno, D. Vitagliano, T. Guida, Fortunato Ciardiello, G. Tortora, G. Vecchio, A. Ryan, G. Fontanini, A. Fusco, M. Santoro. Cancer Research, 2002

632 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/d29c6bea05c4a37f124d36ac612ed2c6c053fd52

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. J. Fagin
2. M. Schlumberger
3. R. Elisei
4. H. Dralle
5. S. Wells
6. P. Langmuir
7. B. Robinson
8. R. Gagel

Citations in the corpus

• Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. (2012, background): “Vandetanib is a once-daily oral agent that selectively targets RET, VEGFR, and EGFR signaling.(12,16) We report the results of an international, randomized, placebo-controlled, double-blind, phase III study (ZETA) to evaluate vandetanib 300 mg/d in patients with locally advanced or metastatic MTC.”